desloratadine 0.5mg/ml oral solution
rosemont pharmaceuticals ltd - desloratadine - oral solution - 0.5mg/ml - antihistamines – h1 antagonist - it is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with: - allergic rhinitis - urticaria
paracetamol 500mg tablets
aspar pharmaceuticals ltd - paracetamol - oral tablet - 500mg
aspirin 300mg tablets
aspar pharmaceuticals ltd - aspirin - oral tablet - 300mg
lmx 4 cream
ferndale pharmaceuticals ltd - lidocaine - cutaneous cream - 40mg/1gram
lidocaine 4% cream
colorama pharmaceuticals ltd - lidocaine - cutaneous cream - 40mg/1gram
akynzeo
rafa laboratories ltd - netupitant; palonosetron as hydrochloride - capsules - netupitant 300 mg; palonosetron as hydrochloride 0.50 mg - palonosetron, combinations - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
venclexta 10 mg tablets
abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 10 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.
venclexta 100 mg tablets
abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 100 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.
venclexta 50 mg tablets
abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 50 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.
zemplar 1 microgram
abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules soft - paricalcitol 1 mcg - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.